A Phase 1 Drug-Drug Interaction Study of the Effects of XL184 on the Pharmacokinetics of a Single Oral Dose of Rosiglitazone in Subjects With Solid Tumours.
Phase of Trial: Phase I
Latest Information Update: 28 Oct 2015
At a glance
- Drugs Cabozantinib (Primary) ; Rosiglitazone
- Indications Renal cancer; Solid tumours; Thyroid cancer
- Focus Pharmacokinetics; Registrational
- 18 Sep 2013 Status changed from active, no longer recruiting to completed as reported by ClinicalTrials.gov.
- 02 Jun 2012 Interim results from a cohort of renal cell carcinoma patients have been presented at ASCO-2012 according to an Exelixis media release. Results were also summarised in the media release.
- 24 May 2012 Planned end date changed from 1 Dec 2011 to 1 Aug 2012 as reported by ClinicalTrials.gov.